Molecular Encapsulation of Thalidomide with Sulfobutyl Ether-7 β-Cyclodextrin for Immediate Release Property: Enhanced In Vivo Antitumor and Antiangiogenesis Efficacy in Mice

REFERENCES

• Bauer K. S., Dixon S. C., Figg W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochemical Pharmacology 1998; 55: 1827–1834
   PubMed Web of Science ®Google Scholar
• Chen T. L., Vogelsang G. B., Petty B. G., Brundrett R. B., Noe D. A., Santos G. W., Colvin O. M. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metabolism and Disposition 1989; 17: 402–405
   PubMed Web of Science ®Google Scholar
• Corrigan O I., Stanley T. Mechanism of drug dissolution enhancement from β-cyclodextrin-drug systems. Journal of Pharmacy and Pharmacology 1982; 34: 621–626
   PubMed Web of Science ®Google Scholar
• Dredge K., Horsfall R., Robinson S. P., Zhang L-H, Ling L., Yang T., Shirley M. A., Muller G., Schafer P., Stirling D., Dalgleish A. G., Bartlett J. B. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research 2005; 69: 56–63
   PubMed Web of Science ®Google Scholar
• Goosen C., Laing T. J., Plessis J., Du Goosen T. C., Lu G.W., Flynn G. L. Percutaneous delivery of thalidomide and its N-alkyl analogs. Pharmaceutical Research 2002; 19: 434–439
   PubMed Web of Science ®Google Scholar
• Grosse P. Y., Francoise B., Pinguet F. Methyl-b-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: Effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemotherapy and Pharmacology 1997; 40: 489–494
   PubMed Web of Science ®Google Scholar
• Gutman M., Szold A., Ravid A., Lazauskas T., Merimsky O., Klausner J. M. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Research 1996; 16: 3673–3677
   PubMed Web of Science ®Google Scholar
• Higuchi T., Connors K. A. Phase solubility analysis. Advances in. Analytica Chemistry and Instrumentation 1965; 4: 117–212
   Google Scholar
• Hirayama F., Uekama K. Cyclodextrin-based controlled drug release system. Advanced Drug Delivery Reviews 1999; 36: 125–141
   PubMed Web of Science ®Google Scholar
• Kale R. D., Saraf M. N., Juvekar A. S., Tayade P. T. Decreased B16F10 melanoma growth and impaired tumor vascularization using quercetin-cyclodextrin binary system. Journal of Pharmacy and Pharmacology 2006, (In Press)
   PubMed Web of Science ®Google Scholar
• Khan K. A. The concept of dissolution efficiency. Journal of Pharmacy and Pharmacology 1975; 27: 48–49
   PubMed Web of Science ®Google Scholar
• Kim K. H., Frank M. J., Henderson N. L. Application of differential scanning calorimetry to the study of solid drug dispersions. Journal of Pharmaceutical Sciences 1985; 74: 283–289
   PubMed Web of Science ®Google Scholar
• Koch H. P., Steinacker C. Improvement of solubility and stability of thalidomide by inclusion complexation with cyclodextrins. Archives of Pharmazie 1988; 321: 371–373
   PubMed Web of Science ®Google Scholar
• Krenn M., Gamcsik M. P., Vogelsang G. B., Colvin O. M., Leong K. W. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-beta-cyclodextrin. Journal of Pharmaceutical Sciences 1992; 81: 85–689
   PubMed Web of Science ®Google Scholar
• Lipinski C. A., Lombardo F., Dominy B. W. Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 2001; 46: 3–26
   PubMed Web of Science ®Google Scholar
• Loftsson T., Brewster M. E. Pharmaceutical applications of cyclodextrins: 1. Drug solubilization and stabilization. Journal of Pharmaceutical Sciences 1996; 85: 1017–1025
   PubMed Web of Science ®Google Scholar
• Marriott B. J., Westby M., Cookson S., Guckian M., Goodbourne S., Muller G., Shire M. G., Stirling D., Dalgleish A. G. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. The Journal of Immunology 1998; 161: 4236–4243
   PubMed Web of Science ®Google Scholar
• Mura P., Faucci M. T., Parrini P. L., Furlanetto S., Pizauti S. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. International Journal of Pharmaceutics, 179: 117–128
   PubMed Web of Science ®Google Scholar
• Omura T., Sato R. The Carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 1964; 239: 2370–2378
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference55th. Medical Economics, Inc, New Jersey, NJ 2001; 1081–1083
   Google Scholar
• Pollard M. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA III) in L-W rats. Cancer Letters 1996; 101: 21–24
   PubMed Web of Science ®Google Scholar
• Simmons B. R., Lush R. M., Figg W. D. A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Analytica Chimica Acta 1997; 339: 91–97
   Web of Science ®Google Scholar
• Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chemical Reviews 1998; 98: 1743–1754
   PubMed Web of Science ®Google Scholar
• Tayade P., Saraf M., Kale R. Concept, mechanisms, and therapeutics of angiogenesis in cancer and other diseases. Journal of Pharmacy and Pharmacology 2003; 55: 1045–1053
   PubMed Web of Science ®Google Scholar
• Toyoda K., Shoda T., Uneyama C., Takada K., Takahashi M. Carcinogenicity study of β-cyclodextrin in F344 rats. Food Chemistry and Toxicology 1997; 35: 331–336
   PubMed Web of Science ®Google Scholar
• Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chemical Reviews 1998; 98: 2045–2076
   PubMed Web of Science ®Google Scholar
• Walawalkar P., Serai P., Iyer K. Isolation and catalytic competence of different animal liver microsomal fractions prepared calcium-aggregation method. Indian Journal of Pharmaceutical Sciences 2006; 68: 262–265
   Google Scholar